| Alimera Sciences is a pharmaceutical company that focuses on the commercialization and development of ophthalmic pharmaceuticals. Co. focuses on diseases affecting the retina. Co.'s commercial product is ILUVIEN®, an intravitreal implant that treats patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide in the eye, for up to 36 months. ILUVIEN is also used in certain countries in the European Economic Area to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. LUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a needle, which allows for a self-sealing wound. We show 54 historical shares outstanding datapoints in our coverage of ALIM's shares outstanding history.|
Understanding the changing numbers of ALIM shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ALIM versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ALIM by allowing them to research ALIM shares outstanding history
as well as any other stock in our coverage universe.